Age |
≤ 64 years (n = 125) | 94 | 86 | 86 | |
≥ 65 years (n = 113) | 92 | 75 | 75 | 0.81 |
Gender |
Female (n = 88) | 90 | 78 | 78 | |
Male (n = 150) | 94 | 85 | 85 | 0.47 |
Myeloma subtype |
IgG subtype (n = 153) | 96 | 84 | 84 | |
Other subtypes (n = 85) | 88 | 78 | 78 | 0.14 |
Time from myeloma diagnosis to SCC |
≤ 15 months (n = 128) | 95 | 81 | 81 | |
> 15 months (n = 110) | 91 | 85 | 85 | 0.83 |
Extra-osseous lesions |
No (n = 218) | 94 | 82 | 82 | |
Yes (n = 20) | 67 | n.a. | n.a. | 0.19 |
Further osseous lesions |
No (n = 91) | 93 | 86 | 86 | |
Yes (n = 147) | 93 | 76 | 76 | 0.73 |
Time developing motor deficits |
Faster (≤ 14 days) (n = 112) | 93 | 81 | 81 | |
Slower (> 14 days = (n = 126) | 93 | 83 | 83 | 0.79 |
Gait function before the start of RT |
Ambulatory (n = 169) | 95 | 85 | 85 | |
Not ambulatory (n = 69) | 85 | 57 | 57 | 0.08 |
Number of vertebrae involved by SCC |
1-2 (n = 112) | 95 | 87 | 87 | |
≤ 3 (n = 126) | 92 | 77 | 77 | 0.17 |
ECOG performance score |
1-2 (n = 150) | 96 | 86 | 86 | |
3-4 (n = 88) | 83 | 62 | 62 | 0.07 |
Radiotherapy regimen |
Short-course RT (n = 84) | 94 | 69 | 69 | |
Longer-course RT (n = 154) | 93 | 90 | 90 | 0.29 |
Entire cohort (n = 238) | 93 | 82 | 82 | |